Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amersin Life Science Corporation subsidiary Hubei Tongji Benda Ebei Pharmaceutical Company has been awarded a sales contract worth approximately $3.6 million to supply a range of homeostatic, antiviral and other pharmaceuticals in injectable form to Hubei Jiuzhoutong Pharmaceutical Ltd.
Subscribe to our email newsletter
Hubei Jiuzhoutong Pharmaceutical Ltd is one of the largest and the fastest growing privately owned pharmaceutical distribution companies in China, with established sales and distribution networks throughout the country.
“We are pleased to enter into Hubei Jiuzhoutong Pharmaceuticals’ large distribution network,” said Reid Li, president of Amersin Life Sciences Corporation. “This is the first time our subsidiary has received a single contract of this size from such a well-established distributor.”
“Our products will be sold into new markets through their sales network creating additional demand in the future,” Li continued. “It is the beginning of a strategic relationship we believe will lead to many other opportunities.”
The Hubei Tongji subsidiary is already one of the largest capacity producers of small form injectable pharmaceuticals in central China.